Arcus Biosciences, Inc. (RCUS)

USD 15.17

(-5.66%)

Total Assets Summary of Arcus Biosciences, Inc.

Arcus Biosciences, Inc.'s latest annual total assets in 2023 was 1.09 Billion USD , down -18.59% from previous year.
Arcus Biosciences, Inc.'s latest quarterly total assets in 2024 Q1 was 1.29 Billion USD , up 18.08% from previous quarter.
Arcus Biosciences, Inc. reported annual total assets of 1.34 Billion USD in 2022, down -15.51% from previous year.
Arcus Biosciences, Inc. reported annual total assets of 1.59 Billion USD in 2021, up 106.13% from previous year.
Arcus Biosciences, Inc. reported quarterly total assets of 1.18 Billion USD for 2024 Q2, down -8.28% from previous quarter.
Arcus Biosciences, Inc. reported quarterly total assets of 1.19 Billion USD for 2023 Q3, down -2.38% from previous quarter.

Annual Total Assets Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Total Assets of Arcus Biosciences, Inc. (2023 - 2016)

Year	Total Assets	Total Assets Growth
2023	1.09 Billion USD	-18.59%
2022	1.34 Billion USD	-15.51%
2021	1.59 Billion USD	106.13%
2020	772.29 Million USD	280.23%
2019	203.11 Million USD	-26.12%
2018	274.92 Million USD	44.33%
2017	190.48 Million USD	73.64%
2016	109.7 Million USD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	1.29 Billion USD	18.08%
2024 Q2	1.18 Billion USD	-8.28%
2023 Q3	1.19 Billion USD	-2.38%
2023 FY	1.09 Billion USD	-18.59%
2023 Q1	1.25 Billion USD	-6.77%
2023 Q2	1.22 Billion USD	-2.71%
2023 Q4	1.09 Billion USD	-8.06%
2022 FY	1.34 Billion USD	-15.51%
2022 Q3	1.39 Billion USD	-5.62%
2022 Q2	1.47 Billion USD	-4.32%
2022 Q4	1.34 Billion USD	-3.5%
2022 Q1	1.54 Billion USD	-3.04%
2021 Q2	898.77 Million USD	-3.89%
2021 FY	1.59 Billion USD	106.13%
2021 Q4	1.59 Billion USD	89.67%
2021 Q3	839.29 Million USD	-6.62%
2021 Q1	935.11 Million USD	21.08%
2020 FY	772.29 Million USD	280.23%
2020 Q3	811.07 Million USD	68.49%
2020 Q4	772.29 Million USD	-4.78%
2020 Q2	481.38 Million USD	173.29%
2020 Q1	176.14 Million USD	-13.28%
2019 Q2	238.97 Million USD	-7.56%
2019 FY	203.11 Million USD	-26.12%
2019 Q3	216.95 Million USD	-9.21%
2019 Q1	258.53 Million USD	-5.96%
2019 Q4	203.11 Million USD	-6.38%
2018 Q2	293.86 Million USD	-3.78%
2018 FY	274.92 Million USD	44.33%
2018 Q4	274.92 Million USD	-4.11%
2018 Q3	286.72 Million USD	-2.43%
2018 Q1	305.39 Million USD	60.33%
2017 Q1	- USD	0.0%
2017 Q4	190.48 Million USD	0.0%
2017 FY	190.48 Million USD	73.64%
2016 FY	109.7 Million USD	0.0%

Peer Total Assets Comparison of Arcus Biosciences, Inc.

Name	Total Assets	Total Assets Difference
ADC Therapeutics SA	354.78 Million USD	-208.64%
Alto Neuroscience, Inc.	86.62 Million USD	-1164.025%
Annovis Bio, Inc.	10.2 Million USD	-10626.603%
Biohaven Pharmaceutical Holding Company Ltd.	513.21 Million USD	-113.362%
Ginkgo Bioworks Holdings, Inc.	1.66 Billion USD	34.248%
Nuvation Bio Inc.	621.48 Million USD	-76.191%
Nuvation Bio Inc.	621.48 Million USD	-76.191%
Theriva Biologics, Inc.	60.21 Million USD	-1718.605%
Zymeworks Inc.	580.88 Million USD	-88.507%